



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

# Cardiac Troponin T and Troponin I in the General Population: Comparing and Contrasting Their Genetic Determinants and Associations With Outcomes

### Citation for published version:

Welsh, P, Preiss, D, Hayward, C, Shah, ASV, McAllister, D, Briggs, A, Boachie, C, McConnachie, A, Padmanabhan, S, Welsh, C, Woodward, M, Campbell, A, Porteous, D, Mills, NL & Sattar, N 2019, 'Cardiac Troponin T and Troponin I in the General Population: Comparing and Contrasting Their Genetic Determinants and Associations With Outcomes', *Circulation*, vol. 139, no. 24, pp. 2754–2764. <https://doi.org/10.1161/CIRCULATIONAHA.118.038529>

### Digital Object Identifier (DOI):

[10.1161/CIRCULATIONAHA.118.038529](https://doi.org/10.1161/CIRCULATIONAHA.118.038529)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Peer reviewed version

### Published In:

Circulation

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Cardiac Troponin T and Troponin I in the General Population: Comparing and Contrasting their Genetic Determinants and Associations with Outcomes

**Running Title:** *Welsh et al.; cTnI & cTnT Comparison*

Paul Welsh, PhD<sup>1</sup>; David Preiss, PhD<sup>2</sup>; Caroline Hayward, PhD<sup>3</sup>; Anoop S.V. Shah, MD<sup>4</sup>;  
David McAllister, PhD<sup>5</sup>; Andrew Briggs, PhD<sup>5</sup>; Charles Boachie, MSc<sup>6</sup>;  
Alex McConnachie, PhD<sup>6</sup>; Sandosh Padmanabhan, MD<sup>1</sup>; Claire Welsh, PhD<sup>1</sup>;  
Mark Woodward, PhD<sup>7,8,9</sup>; Archie Campbell, MSc<sup>10,11</sup>; David Porteous, PhD<sup>10</sup>;  
Nicholas L. Mills, MD<sup>4</sup>; Naveed Sattar, FMedSci<sup>1</sup>

<sup>1</sup>Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, United Kingdom; <sup>2</sup>MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom; <sup>3</sup>MRC Human Genetics Unit MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; <sup>4</sup>BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; <sup>5</sup>Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom; <sup>6</sup>Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom; <sup>7</sup>The George Institute for Global Health, University of New South Wales, Sydney, Australia; <sup>8</sup>The George Institute for Global Health, University of Oxford, Oxford, United Kingdom; <sup>9</sup>Department of Epidemiology, Johns Hopkins University, Baltimore, MD; <sup>10</sup>Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; <sup>11</sup>Usher Institute for Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom

## Address for Correspondence:

Paul Welsh, PhD  
BHF Glasgow Cardiovascular Research Centre  
University of Glasgow, 126 University Place  
Glasgow G12 8TA, UK  
Tel: 0141 330 2569  
Email: [Paul.Welsh@glasgow.ac.uk](mailto:Paul.Welsh@glasgow.ac.uk)

## Abstract

**Background:** There is great interest in widening the use of high sensitivity cardiac troponins for population cardiovascular disease (CVD) and heart failure screening. However, it is not clear whether cardiac troponin T (cTnT) and troponin I (cTnI) are equivalent measures of risk in this setting. We aimed to compare and contrast i) the association of cTnT and cTnI with CVD and non-CVD outcomes, and ii) their determinants in a Genome wide association study (GWAS).

**Methods:** High-sensitivity cTnT and cTnI were measured in serum from 19,501 individuals in Generation Scotland Scottish Family Health Study. Median follow-up was 7.8 years (Q1-Q3 7.1-9.2). Associations of each troponin with a composite CVD outcome (1,177 events), CVD death (n=266), non-CVD death (n=374), and heart failure (n=216) were determined using Cox models. A genome-wide association study was conducted using a standard approach developed for the cohort.

**Results:** Both cTnI and cTnT were strongly associated with CVD risk in unadjusted models. After adjusting for classical risk factors, the hazard ratio for a one standard deviation increase in log transformed troponin was 1.24 (95%CI 1.17-1.32) and 1.11 (1.04-1.19) for cTnI and cTnT, respectively; ratio of HRs 1.12 (1.04-1.21). cTnI, but not cTnT, was associated with MI and CHD. Both cTnI and cTnT had strong associations with CVD death and heart failure. By contrast, cTnT, but not cTnI, was associated with non-CVD death; ratio of HRs 0.77 (0.67-0.88). We identified five loci (53 individual SNPs) that had GWAS significant associations with cTnI, and a different set of four loci (4 SNPs) for cTnT.

**Conclusions:** The upstream genetic causes of low grade elevations in cTnI and cTnT appear distinct, and their associations with outcomes also differ. Elevations in cTnI are more strongly associated with some CVD outcomes, whereas cTnT is more strongly associated with the risk of non-CVD death. These findings help inform selection of an optimal troponin assay for future clinical care and research in this setting.

**Key Words:** Cardiovascular disease risk factors; genetics; troponin; troponin T

## Clinical Perspective

### What is new?

- High sensitivity cardiac troponin I and troponin T have different associations with health outcomes, including specific CVD outcomes, in the general population.
- Upstream genetic causes of elevated cardiac troponin I and troponin T in healthy people also appear distinct from each other.

### What are the clinical implications?

- Cardiac troponin I appears to be a more specific marker of risk of composite CVD and coronary heart disease, while cardiac troponin T is more strongly associated with risk of non-CVD death.
- Both cardiac troponin I and cardiac troponin T were associated with HF and CVD death.
- These findings help inform selection of an optimal troponin assay for future clinical care and research in the general population.

Circulation

## Introduction

The 99<sup>th</sup> centile of high sensitivity cardiac troponin T (cTnT) and troponin I (cTnI), derived from a normal reference population, is used to detect myocardial necrosis as part of a diagnosis of myocardial infarction<sup>1,2</sup>. However, low grade elevations in troponin in the general population, well below the diagnostic threshold, are also associated with future cardiovascular disease (CVD) events and may have a role in screening the general population for CVD risk<sup>3,4</sup>.

In existing cohort studies, high sensitivity cTnI or cTnT are frequently measured individually without an evidence-based decision as to which biomarker might be preferable to achieve a specific aim. This is reflected in a recent study level meta-analysis where thirteen studies measured cTnI and seven studies measured cTnT, although none measured both<sup>4</sup>. One study has compared the performance different cTnI assays in the general population<sup>5</sup>. Our own recent data highlight differential cross-sectional associations of cTnI and cTnT with classical CVD risk factors, and their relatively weak association with each other in a general population<sup>6</sup>. Therefore, there is a need for a systematic approach to compare high sensitivity cTnI and cTnT and their associations with a range of CVD and non-CVD health outcomes. Such a study has the potential to prioritise which of these assays should be used to improve CVD risk prediction, and for future measurement in established biobanks.

As a separate issue, the causal upstream determinants of troponin elevation in the general population are not clear. The use of genetic variants to investigate potential causal pathways is now well established<sup>7</sup>. A genome wide association study (GWAS) of 11,544 individuals has been reported for cTnT<sup>8</sup>, but there is currently limited data reported on genetic determinants of either troponin. Contrasting the upstream genetic determinants of low grade elevations in cTnI

and cTnT would allow further mechanistic insight into potential differences in their causal determinants.

Using clinical high sensitivity assays, we measured both cTnT and cTnI in 19,501 individuals in the Generation Scotland Scottish Family Health Study (GS:SFHS). We aimed to contrast the associations of cTnI and cTnT with risk of CVD and non-CVD health outcomes, and to conduct a GWAS for both of the biomarkers to investigate differences in both the causes and consequences of their elevation.

## Methods

The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure subject to a successful project application to the Generation Scotland Access Committee, and requisite associated ethical approval for access to linked health data from NHS Scotland.

### Study recruitment

The recruitment and design of GS:SFHS has been reported elsewhere<sup>9,10</sup>. During 2006-2010 potential participants (aged 35-65 years) were identified and invited at random from collaborating general medical practices in Scotland. Participants were asked to identify  $\geq$ one first-degree relative aged  $\geq$ 18 years who would also be able to participate. Subsequently, 21,476 participants aged between 18 and 98 years attended a staffed research clinic in Scotland. Participants completed a health questionnaire, and had physical and clinical characteristics measured according to a standardised protocol<sup>10</sup>. Past medical history, including a diagnosis of diabetes mellitus (type 1 or type 2) and cardiovascular disease (prior myocardial infarction or stroke), and use of medications was self-reported. Family history of CVD was defined as a self-

report of parents or siblings having heart disease or stroke. Fasting blood samples were taken, according to a standard operating procedure, and serum samples were separated. Baseline biochemistry including total cholesterol, HDL cholesterol, and serum creatinine, were measured at the time of collection and additional serum aliquots were stored at  $-80^{\circ}\text{C}$  for future biochemical analyses. Scottish Index of Multiple Deprivation (SIMD) scores, nationally compiled composite measures of small-area deprivation, were derived from participant postcodes<sup>11</sup>. The study obtained written informed consent from all participants and received ethical approval from the National Health Service Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89).

### Measurement of high sensitivity troponins



High sensitivity cTnT (Roche Diagnostics, Basel, Switzerland) and high sensitivity cTnI (ARCHITECT STAT, Abbott Laboratories, Abbott Park, IL, Abbott Diagnostics) were measured on Cobas e411 and i1000SR analysers respectively, using the manufacturers calibrators and quality controls<sup>6</sup>. We also participated in the UK National External Quality Assurance Scheme for these biomarkers during the conduct of study. The limit of blank (LoB) of the cTnT assay is set to 3ng/L by the manufacturer, while we reported anything less than 1.2ng/L for cTnI as below the limit of blank<sup>12</sup>. Results below the LoB (“undetectable”) are reported as half of the limit of blank (i.e. 1.5ng/L for cTnT and 0.6ng/L for cTnI) for continuous analyses. A total of 19,501 individuals provided measurements of both troponins.

### Health outcomes

Participants were followed to the end of September 2017 for deaths or hospitalisations for events of interest. Outcomes were identified using a national database: the Information Services Division National Health Service record linkage for Scotland. This contains information on

Scotland's morbidity records for acute specialty day case and inpatient discharges from hospital (Scotland's morbidity record [SMR] 01) since January 1981. Causes of death, derived from death certificates, were obtained from National Health Service Central. For this study, the primary composite CVD outcome was any event included in the national ASSIGN risk score definition of CVD<sup>13</sup>, including any ICD-10 codes I20-25, G45, I60-69, as well as death from CVD (I00-I99), and OPCS4 procedure codes L29.5, L31.1, K40-46, K49, and K75 (procedures comprising carotid endarterectomy, carotid angioplasty, coronary artery bypass graft, and percutaneous transluminal coronary angioplasty). CVD death included deaths coded from underlying causes I00-I99; all others were classified as non-CVD deaths. Other clinical outcomes (fatal or non-fatal) included coronary heart disease (I00-I25), myocardial infarction (I21, I22), ischaemic stroke (I63, I64, G45), any malignancy (C00-C97), and hospitalisation for heart failure (I50, I42.0, I42.6, I42.7, I42.9, I11.0).

## GWAS

Details on blood collection and DNA extraction are provided elsewhere<sup>14</sup>. Samples were genotyped using the Illumina Human OmniExpressExome-8v1.0 Bead Chip and Infinium chemistry and processed using the Illumina Genome Studio Analysis software v2011 (Illumina, San Diego, CA, USA). Quality control was performed to remove SNPs with <98% call rate, individuals with a genotyping rate <98% and SNPs with a Hardy Weinberg equilibrium test p-value  $\leq 1 \times 10^{-6}$  and a minor allele count of <50. Individuals who were identified as population outliers through principal component analyses of their genotypic information were also removed<sup>15</sup>. Following quality control there were 19,904 GS:SFHS individuals (11,731 females and 8173 males) that had genotypic information for 561,125 autosomal SNPs, with 19,130 participants having phenotyping for at least one troponin. In order to increase the density of variants



throughout the genome, the genotyped data were imputed utilising the Sanger Imputation Service (<https://imputation.sanger.ac.uk/>) using the HRC panel v1.1<sup>16</sup>. Autosomal haplotypes were checked to ensure consistency with the reference panel (strand orientation, reference allele, position) then pre-phased using Shapeit2 v2r837<sup>17,18</sup> the Shapeit2 duohmm option<sup>11</sup><sup>19</sup>, taking advantage of the cohort family structure in order to improve the imputation quality. Monogenic and low imputation quality (INFO < 0.4) variants were removed from the imputed dataset leaving 24,111,857 variants available for downstream analysis.

### Statistical analysis for risk associations

The intra-class correlation coefficients for cTnT and cTnI were 0.18 (95%CI 0.16, 0.19) and 0.09 (95%CI 0.07, 0.10) respectively, for clustering within family groups. Allowing for familial clustering had no appreciable effect on any analyses, so the results presented here are from analyses without adjustment for clustering. Multiple imputation by chained equations (MICE) was used to account for missing data for classical risk factors (but not missing troponin concentrations) in regression models. Ten imputed datasets were used.

To illustrate associations of troponins and classical risk factors with health outcomes, available complete data were presented using categorical variables expressed as frequencies and percentages, and continuous variables as medians (interquartile interval) or mean (standard deviation). Each troponin was split into three unequal groups (low; cTnT <3.0ng/L & cTnI ≤1.8ng/L, intermediate; cTnT 3.0-5.7ng/L & cTnI 1.9-3.0ng/L, high cTnT ≥5.8ng/L & cTnI ≥3.1ng/L, so that the proportion within each grouping was similar for each troponin. Kaplan Meier curves were used to illustrate the association of the three groups of each troponin with incident CVD.

Unadjusted and adjusted (for age, sex, total cholesterol, HDL-cholesterol, systolic blood pressure, number of cigarettes smoked per day, rheumatoid arthritis, diabetes, SIMD, family history of CVD, cholesterol lowering medication, blood pressure lowering medication and baseline CVD). Cox proportional hazards models were used to investigate the association of the troponins with health outcomes. Further adjustment for BMI and creatinine made no substantial difference (data not shown). The shapes of the associations were tested and illustrated using restricted cubic splines (knots at 2,3,5,10, and 25pg/ml for cTnI, and at 3.3, 5, 8, 10, and 25pg/ml for cTnT) and also modelled using troponins as continuous risk factors (per 1 standard deviation increase after log-transformation). The proportional hazards assumption was tested by plotting Schoenfeld residuals. Tests for interaction of cTnT and cTnI with CVD events were also conducted by baseline classical risk factors. The 95% CI for the difference in the log hazard ratio for cTnI and cTnT was obtained by bootstrapping (5000 times); exponentiation of the difference in the log hazard ratios gives the ratio of the hazard ratios. Improvement in the clinical prediction of primary CVD (using age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, number of cigarettes per day, SIMD, diabetes, family history of CVD, and rheumatoid arthritis) on addition of each troponin individually was tested (in participants without baseline CVD and aged  $\geq 40$  years) using the continuous net reclassification index and integrated discrimination index. These tests were conducted using the nricens package (R) with 5000 bootstraps. All analyses were performed in STATA (version 14.2) and R (version 3.3.1).

### **Statistical analysis for GWAS**

GS:SFHS has previously been used in a variety of GWAS studies and the imputed data is research ready<sup>20,21</sup>. There were 19,130 individuals with a troponin result and quality-controlled genomic data.

Genome-wide associations were performed on HRC-imputed data, only results from variants with a minor allele count of 50 in our sample. For each phenotype, an additive model for the fitted SNP fixed effect was set up incorporating age and sex as covariates and a random polygenic effect accounting for relatedness among participants. Phenotypes were inverse-normal transformed to ensure a normal distribution of the model's residuals, using the 'rntransform' function in the GenABEL R package<sup>22</sup>. Associations with the HRC imputed variants were performed with the software RegScan v0.2<sup>23</sup>. The pgsresidualY estimated from the polygenic function in GenABEL was used for association analysis. The effect size, standard errors and *p* values were thereafter corrected to account for relatedness using the GRAMMAR-Gamma factors also provided by the 'polygenic' function<sup>24</sup>. The 'polygenic' command in the GenABEL R package was used to calculate Genetic kinship-based heritability. The standard errors of heritability estimates were obtained by re-running the 'polygenic' command and fixing the heritability to 0.

GWAS significance of SNPs is attained at a *p*-value of  $<5 \times 10^{-8}$ , and suggestive hits at *p*-value  $<1 \times 10^{-5}$ . Manhattan plots are used to illustrate hits using these thresholds. All suggestive hits for both troponins were read into FUMA<sup>25</sup> (<http://fuma.ctglab.nl/snp2gene>) to identify loci of interest and functional annotations. The 1000 genomes European reference panel (phase 3) was used to account for LD in the sample. For the primary analyses, we focused only on SNPs that attained a GWAS significant association, with a further sensitivity analysis using a more relaxed criteria for exploration; the minimum value of a lead SNP was taken at a *p*-value of  $<5 \times 10^{-7}$ , and without a minimum minor allele frequency, to maximise loci identification. However, interpretation of results in this sensitivity analysis should place less emphasis on rare isolated variants

## Results

### Crude associations of troponins with classical risk factors and with CVD

Detectable concentrations of cTnI and cTnT were found in 14579 participants (74.8%) and 10395 participants (53.3%) respectively. Both troponins were generally associated with adverse classical CVD risk factors, with the exception that cTnI and cTnT were inversely associated with current smoking, and cTnT was inversely associated with total cholesterol (supplemental table 1). The Spearman correlation coefficient between cTnT and cTnI was  $r=0.443$  ( $p<0.001$ ).

Median follow-up was 7.8 years (Q1-Q3 7.1-9.2) for the primary composite CVD endpoint. Of the 19,501 participants 1,177 experienced an incident CVD during follow-up (6.0%), 640 participants died (3.3%), and 266 died from CVD causes (1.4%). Participants who experienced the composite CVD outcome generally had a more adverse risk factor profile including being older, more frequently being male, having a higher BMI, higher blood pressure, lower HDL-cholesterol (but also a lower total cholesterol), a higher deprivation score, were more frequently smokers, and were more likely to have baseline CVD, diabetes or rheumatoid arthritis, or to be taking cholesterol or blood pressure lowering medication (Table 1). Those who experienced a composite CVD event had almost a 2-fold higher median baseline cTnI and cTnT (Table 1). Similar results were found for other outcomes of interest; both troponins were higher in those who experienced every adverse outcome of interest (supplemental tables 2-9). Kaplan Meier curves show that both cTnI and cTnT were associated with the probability of CVD-free survival (both log rank tests  $p<0.001$ ) (supplemental figure 1).

### Shape of the association of troponins with outcomes

Using undetectable levels of each troponin as the referent, the association of elevated troponin with composite CVD was explored by restricted cubic splines (Fig 1). For both cTnI and cTnT

there was a rapid rise in risk in unadjusted models. For instance at a cTnI level of 5ng/L the HR was 7.7 (95% CI 6.3-9.3), compared to undetectable cTnI, and at 20ng/L was 12.8 (9.9-16.5). The corresponding HRs for cTnT were 2.2 (1.9-2.7) and 12.2 (10.1-14.9), respectively. For both troponins, there was a levelling off in increasing risk at higher levels of troponin. Adjustment for classical risk factors attenuated the associations for both troponins substantially, and made the associations more linear. In the adjusted model, at values of 5ng/ml and 20ng/L, the HRs were 1.5 (1.2-1.9) and 2.6 (1.9-3.4) for cTnI, and 0.97 (0.80-1.17) and 1.4 (1.1-1.8) for cTnT, respectively. The associations of both troponins with CVD death was more pronounced (supplemental figure 2). Only cTnT showed trends towards a positive relationship with non-CVD death in adjusted models (supplemental figure 3) and therefore had stronger associations with all cause mortality (supplemental figure 4). Only cTnI, not cTnT, was associated with MI and CHD (supplemental figure 5 & 6), and adjustment for age and sex alone was sufficient to ameliorate the association between cTnT and MI or CHD (data not shown). Both cTnI and cTnT were associated with ischaemic stroke and heart failure (supplemental figure 7 & 8). After adjustment, neither troponin was associated with cancer (supplemental figure 9).

A higher category (low/intermediate/high) of cTnI was associated with increased unadjusted rate of composite CVD within each category of cTnT (Fig 2). Likewise, a higher category of cTnT was associated with increased rate of composite CVD within each category of cTnI (Fig 2). After controlling for cTnT, each category increase in cTnI had a HR of 1.92 (95%CI 1.77-2.07) for composite CVD compared to the preceding category. After controlling for cTnI, the HR for one category increase in cTnT was 1.64 (95%CI 1.52-1.78).

### **Comparison of the association of cTnI and cTnT with outcomes**

We then compared the extent of the adjusted association of cTnI and cTnT with the different

outcomes. One standard deviation increase in log cTnI was associated with a HR of 1.24 for composite CVD, whereas the HR was 1.11 for one standard deviation increase in log cTnT. The ratio of these hazard ratios indicates the association with composite CVD was stronger for cTnI: 1.12 (95%CI 1.04-1.21) (Table 2). Both troponins had similarly strong associations with CVD death, and both had stronger associations with CVD death than for the composite CVD outcome (Table 2). Both troponins were also strongly associated with heart failure (Table 2). cTnT, but not cTnI, had an association with non-CVD death (ratio of HRs 0.77 (95% CI 0.67-0.88)), and consequently cTnT also had a stronger association with all cause death than cTnI (Table 2). In contrast, only cTnI was associated with MI or CHD; cTnT showed no association with either outcome. Both troponins showed an association with ischaemic stroke, and neither were associated with incident cancer after adjustment (Table 2). When both cTnI and cTnT were included in the same adjusted model together, only cTnI remained associated with the composite CVD outcome (Table 3).

### **Interaction by classical risk factors**

Investigating interactions by baseline risk factors for the composite CVD outcome, both cTnI and cTnT showed trends to be less strongly associated with composite CVD among those with baseline CVD or taking blood pressure or cholesterol lowering medications (supplemental figure 10). cTnI was more strongly associated with composite CVD risk among patients with diabetes (p for interaction 0.009) (supplemental figure 10). There were no other notable interactions.

### **Primary composite CVD prediction models**

Using the continuous net reclassification index, a clinical prediction model in those without baseline CVD and aged  $\geq 40$  years (n=12,496) was improved by the addition of cTnI which yielded a continuous net reclassification index improvement of 7.7% (95%CI 2.8%, 11.7%;

p=0.004), and an integrated discrimination index of +0.005 (95%CI 0.002, 0.009; p<0.001). The clinical prediction model also showed a trend to be improved by addition of cTnT separately, yielding a continuous net reclassification index improvement of 8.0% (95%CI -2.3%, 11.9%; p=0.064), and an integrated discrimination index of +0.001 (95%CI 0.000, 0.002; p=0.001).

### **GWAS for cTnI and cTnT**

Heritability of cTnI was  $0.249 \pm 0.013$  and cTnT was  $0.35 \pm 0.011$ . There were 5 loci for cTnI that reached genome wide significance (Fig 3a). These included SNPs at *KLKB1* (4q35.2: 23 SNPs at GWAS significance), *VCL/AP3M1/ADK* (10q22.2: 2 SNPs), *ANO5* (11p14.3: 14 SNPs), *CEP95/SMURF2* (17q23.3: 3 SNPs), and *LMANI/CPLX4* (18q21.32: 11 SNPs) genes (Table 4). There was an isolated intergenic SNP in chromosome 1 that was of borderline genome wide significance, flanking a suggestive hit for *DABI* (1p32.1) SNP. There were marked differences in the GWAS Manhattan plot for cTnT compared to cTnI (Fig 3b), with limited overlap of associated loci, and far fewer suggestive loci associated with cTnT in general. There were isolated low frequency SNPs at the genes of *C1orf112*, *TRABD2A* (2p11.2), *SORBS2* (4q35.1), and *PTPRD* (9p23) for cTnT (Table 4).

Using a more relaxed threshold for statistical significance identified other loci of potential interest. For cTnI, a locus at *F12/GRK6* (5q35.3: 5SNPs) also showed suggestive trends towards association (Supplemental table 10). For cTnT there was also a suggestive hit for a locus at *POC1B* (12q21.33: 16 SNPs), and *TMEM131/ZAP70* (2q11.1: 4 SNPs). Excluding those with baseline CVD had minimal impact on the primary genetic associations (Supplemental table 11).

## Discussion

This study highlights several important findings that are relevant to potential future clinical use of high sensitivity troponins in CVD risk prediction, and also relevant to scientific enquiries into the aetiology of elevated troponin in apparently healthy people. Most remarkably, we demonstrate the striking differences in cTnI and cTnT in terms of their association with composite CVD and with specific CVD outcomes. Both have similar strong associations with risk of CVD death and heart failure, and both have associations with ischaemic stroke. Most surprisingly however, cTnT showed no association with MI or CHD after adjusting for classical risk factors; cTnI did. As a result, cTnI was more strongly associated with the primary composite CVD outcome. In fact, cTnT showed an association with non-CVD death while cTnI did not. These findings suggest different upstream causes of modest elevations in cTnI and cTnT in the general population. In line with this, our GWAS highlights little overlap in the genetic determinants of circulating cTnI and cTnT. This is in line with our previous report, demonstrating differences in the associations of classical risk factors with the troponins in a cross-sectional study <sup>6</sup>.

In a recent study level meta-analysis <sup>4</sup>, in the top vs bottom third of the population for each troponin, the hazard ratio of CVD was nominally stronger for cTnT than cTnI (HR=1.60 vs 1.36;  $p=0.171$ ), and cTnT was more strongly associated with fatal CVD ( $p=0.027$ ). However, the troponins were measured in different cohorts, which limits the ability to make direct comparisons. Our study is the first large general population study of which we are aware to compare systematically the disease associations of the two troponins directly.

The lack of association of cTnT with MI and CHD, after adjusting for classical risk factors is unexpected, given that the source of both troponins is cardiac injury. Indeed, previous



studies demonstrate that cTnT is associated with LV hypertrophy<sup>26</sup> and coronary plaque count as well as plaque phenotype<sup>27,28</sup>. The MI and CHD outcomes were associated with cTnT in unadjusted models, and with cTnI in adjusted models, so the lack of association is not explained by outcome misspecification. Given the additional association of cTnT with fatal-non CVD events, it is interesting to speculate what causes cTnT elevation beyond classical risk factors in apparently healthy people. cTnT is known to be transiently expressed in foetal skeletal muscle<sup>29</sup> and it may be possible that non cardiac tissues express cTnT in some circumstances. For instance, patients with neuromuscular diseases but with no evidence of heart disease may have elevated cTnT, but not an elevated cTnI<sup>30-32</sup>. cTnT is also known to be a strong predictor of adverse non-cardiac outcome following abdominal surgery<sup>33</sup>. As such, different aetiological causes of elevations in cTnI and cTnT, and consequently different downstream risks, may be sufficient to explain our findings.

Upstream genetic determinants of the troponins also appear distinct. For cTnI, the *KLKB1* and *F12* genes are both part of the kallikrein-kinin axis and loci have been associated with biomarkers of endothelin-1, pro-adrenomedullin<sup>34</sup>, B-type natriuretic peptide<sup>35</sup>, as well as L-arginine<sup>36</sup>. Given this broad association with vasoactive peptides, it is interesting that the loci are associated with cTnI, but no association is seen for cTnT. Plasma prokallikrein is activated by active factor XII (encoded by *F12*) and colocalizes to endothelial cells. Activated kallikrein is also involved in processing vasoactive peptides such as bradykinin and renin<sup>37</sup>. The loci around VCL encode vinculin membrane associated protein, which is perhaps particularly relevant to troponin expression, as it appears involved in cytoskeletal modelling in diseased cardiac tissue<sup>38,39</sup>. The anoctamin-5 protein encoded by *ANO5* is a poorly characterised chloride channel found in skeletal and cardiac muscle, and mutations may be associated with cardiomyopathy<sup>40</sup>. Allelic

variants of *LMAN1* gene are associated with factor V-factor VIII deficiency<sup>41</sup>. In contrast, genes associated with cTnT include *ArgBP2* (*SORBS2*) which is highly abundant in cardiac z-disc structures<sup>42</sup>. There is hence a strong biological background for many of these genes being associated with cardiac injury or troponin leakage.

Strengths of the study include the use of a large and well-phenotyped prospective nationwide population study of broadly healthy people, where national record linkage has been used for follow-up. Numbers of outcomes lend the study considerable statistical power. The direct comparisons of cTnI and cTnT in terms of risk associations in a general population is novel, and is supported by the GWAS in a cohort with an established approach to such studies. Weaknesses include the family structure of the study, although sensitivity analyses suggest family clustering had very limited impact on data in terms of clustering within families. The study population is not ethnically diverse, limiting generalisability in that regard, but includes a wide age range from participants of both sexes. In common with many electronic health records, the small proportion of the population who emigrate from Scotland<sup>43</sup> will not have recorded outcomes of interest, but might still be considered “at risk” in our models. This may slightly bias estimates, but is unlikely to affect the direct comparison between biomarkers. A large proportion of participants had undetectable troponin. This is suboptimal for continuous statistical analyses, but we demonstrate results using a number of different models. We also acknowledge that in individual patients, as opposed to population studies, accurate measurement of low troponin levels would be important in using troponin levels to determine clinical risk. Our observations offer limited causal insight as to the reasons underlying differential associations of cTnI and cTnT with different outcomes. However, aetiological differences in the upstream causes of different troponin elevations are supported by GWAS, and as such our data are sufficient to

indicate that care should be taken when selecting a high sensitivity troponin to use as a biomarker in general population studies, or as surrogate biomarkers in trials, depending on the aims of the study.

In conclusion we demonstrate that routine clinical cTnI and cTnT assays have different associations with composite cardiovascular, and non-CVD mortality, outcomes in apparently healthy people; the cTnI assay is specific for cardiovascular disease risk, whereas the cTnT assay is more strongly associated with non-CVD mortality. It also appears that their genetic determinants are largely distinct. Future research studies should use this evidence base to select a troponin for cohort phenotyping depending on the study aims. This information is also of relevance to attempts to improve CVD risk stratification in the population using cardiac troponin measurements.

### **Acknowledgments**

We thank Josephine Cooney and Philip Stewart (University of Glasgow, UK) for excellent technical support. We are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses.

### **Sources of Funding**

Troponin measurements and analysis were supported by a Stratified Medicine Grant from the Chief Scientist Office of the Scottish Government Health Directorates (ASM/14/1). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government

Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping of the samples was carried out by the Genetics Core Laboratory at the Clinical Research Facility, University of Edinburgh, Edinburgh, Scotland and was funded by the Medical Research Council UK. David Preiss is supported by a University of Oxford British Heart Foundation Centre of Research Excellence Senior Transition Fellowship (RE/13/1/30181). Nicholas L Mills is supported by a Butler British Heart Foundation Senior Clinical Research Fellowship (FS/16/14/32023). Caroline Hayward is supported by a Medical Research Council University Unit Programme Grant “QTL in Health and Disease” MC\_PC\_U127592696

## Disclosures



Dr Welsh has received grant support from Roche and Boehringer Ingelheim. Dr Shah has received honoraria from Abbott Diagnostics. Dr Mills has acted as a consultant for Abbott Diagnostics, Roche, Beckman-Coulter, and Singulex. Dr Sattar has received fees for consulting, speaking, and/or honoraria from Roche Diagnostics, Astrazeneca, Boehringer Ingelheim, NovoNordisk, Amgen, Sanofi/Regeneron, and Janssen

## References

1. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2016;37:267–315.
2. National Institute of Health Care and Clinical Excellence (NICE). Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays)/ <https://www.nice.org.uk/guidance/dg15> [accessed 1/17/19]
3. Ford I, Shah ASV, Zhang R, McAllister DA, Strachan FE, Caslake M, Newby DE, Packard CJ, Mills NL. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of

- Coronary Heart Disease. *J Am Coll Cardiol*. 2016;68:2719–2728.
4. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW, Ford I, Trompet S, Stott DJ, Kearney PM, Mooijaart SP, Kiechl S, Angelantonio E Di, Sattar N. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. *J Am Coll Cardiol*. 2017;70:558–568.
  5. Neumann JT, Havulinna AS, Zeller T, Appelbaum S, Kunnas T, Nikkari S, Jousilahti P, Blankenberg S, Sydow K, Salomaa V. Comparison of Three Troponins as Predictors of Future Cardiovascular Events – Prospective Results from the FINRISK and BiomaCaRE Studies. Obukhov AG, ed. *PLoS One*. 2014;9:e90063.
  6. Welsh P, Preiss D, Shah ASV, McAllister D, Briggs A, Boachie C, McConnachie A, Hayward C, Padmanabhan S, Welsh C, Woodward M, Campbell A, Porteous D, Mills NL, Sattar N. Comparison Between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. *Clin Chem*. 2018;64:1607-1616.
  7. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet*. 2014;23:R89-98.
  8. Yu B, Barbalic M, Brautbar A, Nambi V, Hoogeveen RC, Tang W, Mosley TH, Rotter JJ, deFilippi CR, O'Donnell CJ, Kathiresan S, Rice K, Heckbert SR, Ballantyne CM, Psaty BM, Boerwinkle E, CARDIoGRAM Consortium. Association of Genome-Wide Variation With Highly Sensitive Cardiac Troponin-T Levels in European Americans and Blacks: A Meta-Analysis From Atherosclerosis Risk in Communities and Cardiovascular Health Studies. *Circ Cardiovasc Genet*. 2013;6:82–88.
  9. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, Deary IJ, MacIntyre DJ, Campbell H, McGilchrist M, Hocking LJ, Wisely L, Ford I, Lindsay RS, Morton R, Palmer CNA, Dominiczak AF, Porteous DJ, Morris AD. Cohort profile: Generation Scotland: Scottish family health study (GS: SFHS). The study, its participants and their potential for genetic research on health and illness. *Int J Epidemiol*. 2013;42:689–700.
  10. The University of Edinburgh. Generation Scotland. <https://www.ed.ac.uk/generation-scotland> [accessed 1/17/19].
  11. Scottish Government. The Scottish Index of Multiple Deprivation. <http://www.gov.scot/Topics/Statistics/SIMD> [accessed 1/17/19].
  12. Shah AS V, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry A V, Cruikshank A, Reid A, Stoddart M, Strachan F, Walker S, Collinson PO, Apple FS, Gray AJ, Fox KAA, Newby DE, Mills NL. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *BMJ*. 2015;350:g7873.
  13. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). *Heart*. 2007;93:172–176.
  14. Smith BH, Campbell H, Blackwood D, Connell J, Connor M, Deary IJ, Dominiczak AF, Fitzpatrick B, Ford I, Jackson C, Haddow G, Kerr S, Lindsay R, McGilchrist M, Morton R, Murray G, Palmer CN, Pell JP, Ralston SH, St Clair D, Sullivan F, Watt G, Wolf R, Wright A, Porteous D, Morris AD. Generation Scotland: the Scottish Family Health Study; a new resource for researching genes and heritability. *BMC Med Genet*. 2006;7:74.
  15. Amador C, Huffman J, Trochet H, Campbell A, Porteous D, Wilson JF, Hastie N, Vitart V, Hayward C, Navarro P, Haley CS. Recent genomic heritage in Scotland. *BMC Genomics*. BioMed Central; 2015;16:437.

16. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, Kang HM, Fuchsberger C, Danecek P, Sharp K, Luo Y, Sidore C, Kwong A, Timpson N, Koskinen S, Vrieze S, Scott LJ, Zhang H, Mahajan A, Veldink J, Peters U, Pato C, Duijn CM van, Gillies CE, Gandin I, Mezzavilla M, Gilly A, Cocca M, Traglia M, Angius A, Barrett JC, Boomsma D, Branham K, Breen G, Brummett CM, Busonero F, Campbell H, Chan A, Chen S, Chew E, Collins FS, Corbin LJ, Smith GD, Dedoussis G, Dorr M, Farmaki AE, Ferrucci L, Forer L, Fraser RM, Gabriel S, Levy S, Groop L, Harrison T, Hattersley A, Holmen OL, Hveem K, Kretzler M, Lee JC, McGue M, Meitinger T, Melzer D, Min JL, Mohlke KL, Vincent JB, Nauck M, Nickerson D, Palotie A, Pato M, Pirastu N, McInnis M, Richards JB, Sala C, Salomaa V, Schlessinger D, Schoenherr S, Slagboom PE, Small K, Spector T, Stambolian D, Tuke M, Tuomilehto J, Van den Berg LH, Van Rheenen W, Volker U, Wijmenga C, Toniolo D, Zeggini E, Gasparini P, Sampson MG, Wilson JF, Frayling T, de Bakker PI, Swertz MA, McCarroll S, Kooperberg C, Dekker A, Altshuler D, Willer C, Iacono W, Ripatti S, Soranzo N, Walter K, Swaroop A, Cucca F, Anderson CA, Myers RM, Boehnke M, McCarthy MI, Durbin R; Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet.* 2016;48:1279–1283.
17. Delaneau O, Marchini J, Zagury J-F. A linear complexity phasing method for thousands of genomes. *Nat Methods.* 2012;9:179–181.
18. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. *Nat Methods.* 2013;10:5-6.
19. O'Connell J, Gurdasani D, Delaneau O, Pirastu N, Ulivi S, Cocca M, Traglia M, Huang J, Huffman JE, Rudan I, McQuillan R, Fraser RM, Campbell H, Polasek O, Asiki G, Ekoru K, Hayward C, Wright AF, Vitart V, Navarro P, Zagury JF, Wilson JF, Toniolo D, Gasparini P, Soranzo N, Sandhu MS, Marchini J. A General Approach for Haplotype Phasing across the Full Spectrum of Relatedness. *PLoS Genet.* 2014;10:e1004234.
20. Clarke T-K, Adams MJ, Davies G, Howard DM, Hall LS, Padmanabhan S, Murray AD, Smith BH, Campbell A, Hayward C, Porteous DJ, Deary IJ, McIntosh AM. Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117). *Mol Psychiatry.* 2017;22:1376–1384.
21. Howard DM, Hall LS, Hafferty JD, Zeng Y, Adams MJ, Clarke TK, Porteous DJ, Nagy R, Hayward C, Smith BH, Murray AD, Ryan NM, Evans KL, Haley CS, Deary IJ, Thomson PA, McIntosh AM. Genome-wide haplotype-based association analysis of major depressive disorder in Generation Scotland and UK Biobank. *Transl Psychiatry.* 2017;7:1263.
22. Aulchenko YS, Ripke S, Isaacs A, Duijn CM van. GenABEL: an R library for genome-wide association analysis. *Bioinformatics.* 2007;23:1294–1296.
23. Haller T, Kals M, Esko T, Mägi R, Fischer K. RegScan: a GWAS tool for quick estimation of allele effects on continuous traits and their combinations. *Brief Bioinform.* 2015;16:39–44.
24. Svisheva GR, Axenovich TI, Belonogova NM, Duijn CM van, Aulchenko YS. Rapid variance components-based method for whole-genome association analysis. *Nat Genet.* 2012;44:1166–1170.
25. Watanabe K, Taskesen E, Bochoven A Van, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun.* 2017;8:1826.
26. Lemos JA de, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry

- JD, Das SR, Morrow DA, McGuire DK. Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population. *JAMA*. 2010;304:2503.
27. Oemrawsingh RM, Cheng JM, García-García HM, Kardys I, Schaik RHN van, Regar E, Geuns RJ van, Serruys PW, Boersma E, Akkerhuis KM. High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study. *Atherosclerosis*. 2016;247:135–141.
  28. Laufer EM, Mingels AMA, Winkens MHM, Joosen IAPG, Schellings MWM, Leiner T, Wildberger JE, Narula J, Dieijen-Visser MP Van, Hofstra L. The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T. *Arterioscler Thromb Vasc Biol*. 2010;30:1269–1275.
  29. Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans: A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. *Circ Res*. 1991;69:1226–1233.
  30. Rittoo D, Jones A, Lecky B, Neithercut D. Elevation of cardiac troponin T, but not cardiac troponin I, in patients with neuromuscular diseases: Implications for the diagnosis of myocardial infarction. *J Am Coll Cardiol*. 2014;63:2411–2420.
  31. Wens SCA, Schaaf GJ, Michels M, Kruijshaar ME, Gestel TJM Van, Groen S In 'T, Pijnenburg J, Dekkers DHW, Demmers JAA, Verdijk LB, Brusse E, Schaik RHN Van, Ploeg AT Van Der, Doorn PA Van, Pijnappel WWMP. Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe Disease. *Circ Cardiovasc Genet*. 2016;9:6–13.
  32. Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased Skeletal Muscle: A Noncardiac Source of Increased Circulating Concentrations of Cardiac Troponin T. *J Am Coll Cardiol*. 2011;58:1819–1824.
  33. Noordzij PG, Geffen O van, Dijkstra IM, Boerma D, Meinders AJ, Rettig TCD, Eefting FD, Loon D van, Garde EMW van de, Dongen EPA van. High-sensitive cardiac troponin T measurements in prediction of non-cardiac complications after major abdominal surgery. *Br J Anaesth*. 2015;114:909–918.
  34. Verweij N, Mahmud H, Mateo Leach I, Boer RA de, Brouwers FP, Yu H, Asselbergs FW, Struck J, Bakker SJL, Gansevoort RT, Munroe PB, Hillege HL, Veldhuisen DJ van, Gilst WH van, Silljé HHW, Harst P van der. Genome-wide association study on plasma levels of midregional-proadrenomedullin and C-terminal-pro-endothelin-1. *Hypertens*. 2013;61:602–608.
  35. Musani SK, Fox ER, Kraja A, Bidulescu A, Lieb W, Lin H, Beecham A, Chen M-H, Felix JF, Fox CS, Kao WHL, Kardina SLR, Liu C-T, Nalls MA, Rundek T, Sacco RL, Smith J, Sun Y V, Wilson G, Zhang Z, Mosley TH, Taylor HA, Vasani RS. Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study. *Circ Cardiovasc Genet*. 2015;8:122–130.
  36. Zhang W, Jernerén F, Lehne BC, Chen M-H, Luben RN, Johnston C, Elshorbagy A, Eppinga RN, Scott WR, Adeyeye E, Scott J, Böger RH, Khaw K-T, Harst P van der, Wareham NJ, Vasani RS, Chambers JC, Refsum H, Kooner JS. Genome-wide association reveals that common genetic variation in the kallikrein-kinin system is associated with serum L-arginine levels. *Thromb Haemost*. 2016;116:1041–1049.
  37. Su JB. Different cross-talk sites between the renin–angiotensin and the kallikrein–kinin systems. *J Renin-Angiotensin-Aldosterone Syst*. 2014;15:319–328.

38. Zemljic-Harpe A, Manso AM, Ross RS. Vinculin and Talin. *J Investig Med*. 2009;57:849–855.
39. Kaushik G, Spenlehauer A, Sessions AO, Trujillo AS, Fuhrmann A, Fu Z, Venkatraman V, Pohl D, Tuler J, Wang M, Lakatta EG, Ocorr K, Bodmer R, Bernstein SI, Eyk JE Van, Cammarato A, Engler AJ. Vinculin network-mediated cytoskeletal remodeling regulates contractile function in the aging heart. *Sci Transl Med*. 2015;7:292ra99.
40. Wahbi K, Béhin A, Bécane HM, Leturcq F, Cossée M, Laforêt P, Stojkovic T, Carlier P, Toussaint M, Gaxotte V, Cluzel P, Eymard B, Duboc D. Dilated cardiomyopathy in patients with mutations in anoctamin 5. *Int J Cardiol*. 2013;168:76–79.
41. Zhang B, McGee B, Yamaoka JS, Guglielmone H, Downes KA, Minoldo S, Jarchum G, Peyvandi F, Bosch NB de, Ruiz-Saez A, Chatelain B, Olpinski M, Bockenstedt P, Sperl W, Kaufman RJ, Nichols WC, Tuddenham EGD, Ginsburg D. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. *Blood*. 2006;107:1903–1907.
42. Wang B, Golemis EA, Kruh GD. ArgBP2, a multiple Src homology 3 domain-containing, Arg/Abl-interacting protein, is phosphorylated in v-Abl-transformed cells and localized in stress fibers and cardiocyte Z-disks. *J Biol Chem*. 1997;272:17542–17550.
43. National Records of Scotland. Mid-2017 population estimates Scotland. <https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/population/population-estimates/mid-year-population-estimates/mid-2017> [accessed 1/17/19].



# Circulation



**Table 1.** Association of classical risk factors and Troponin I and Troponin T with composite CVD events

	No incident CVD n=18324	Incident CVD n=1177	p-value
Age (years)	46.1±14.61	62.5±11.6	<0.0001
Male sex	7443 (40.6%)	683 (58.0%)	<0.0001
BMI (kg/m <sup>2</sup> )	26.6±5.2	28.4±5.1	<0.0001
SBP (mmHg)	130.7±17.5	140.7±20.2	<0.0001
Total cholesterol (mmol/L)	5.11±1.07	5.00±1.20	0.0013
HDL chol (mmol/L)	1.47±0.41	1.34±0.41	<0.0001
SIMD (score/10)	1.69±1.44	1.96±1.67	<0.0001
Creatinine	73.3±15.3	81.6±22.3	<0.0001
Cigarettes per day	2.35±6.75	4.05±9.88	<0.0001
Current smoking	2829 (16.0%)	227 (20.0%)	0.0003
Family History of CVD	6953 (38.8%)	451 (38.9%)	0.9095
Rheumatoid arthritis	262 (1.4%)	52 (4.4%)	<0.0001
Baseline CVD	507 (2.8%)	370 (31.4%)	<0.0001
Baseline diabetes	429 (2.3%)	133 (11.3%)	<0.0001
Cholesterol medications	998 (5.4%)	284 (24.1%)	<0.0001
Blood pressure medication	1276 (7.0%)	298 (25.3%)	<0.0001
hsTnT (ng/L)	3.2 [1.5,5.8]	6.2 [3.2,10.7]	<0.0001
hsTnI (ng/L)	1.8 [0.6,3.0]	3.3 [0.6,5.9]	<0.0001

P-values are from independent sample t-tests for continuous variables with normal distribution (i.e. mean ± standard deviation), Mann-Whitney U test for continuous variables with skewed distribution (i.e. median [Q1-Q3], or chi squared test for categorical variables (i.e. n (%))

**Table 2.** Association of troponin I and troponin T (per 1SD increase on the log scale) with risk of different events, adjusted for classical risk factors, and the troponins in separate models

	Troponin I	Troponin T	Ratio of the hazard ratio* (95% CI)
	Hazard ratio (95%CI)	Hazard ratio (95%CI)	
CVD (n=1177)	1.24 (1.17 - 1.32)	1.11 (1.04 - 1.19)	1.12 (1.04-1.12)
CVD death (n=266)	1.56 (1.38 - 1.75)	1.52 (1.31 - 1.77)	1.02 (0.87-1.20)
Non CVD death (n=374)	1.04 (0.92 - 1.17)	1.35 (1.20 - 1.52)	0.77 (0.67-0.88)
All cause death (n=640)	1.25 (1.15-1.36)	1.42 (1.29-1.55)	0.88 (0.80-0.98)
MI (n=259)	1.18 (1.04 - 1.35)	0.93 (0.81 - 1.08)	1.27 (1.07-1.48)
CHD (n=812)	1.19 (1.11 - 1.28)	1.04 (0.96 - 1.13)	1.14 (1.04-1.25)
Ischaemic stroke (n=205)	1.39 (1.21 - 1.60)	1.22 (1.04 - 1.43)	1.15 (0.97-1.36)
Heart failure (n=216)	1.86 (1.66 - 2.08)	1.69 (1.43 - 1.98)	1.10 (0.93 - 1.31)
Cancer (n=1078)	0.96 (0.90 - 1.04)	1.00 (0.93 - 1.07)	0.96 (0.89-1.04)

Model adjusted for age, sex, total cholesterol, HDL-cholesterol, systolic blood pressure, cigarettes smoked per day, rheumatoid arthritis, diabetes, SIMD score, family history of CVD, use of blood pressure medications and use of cholesterol lowering medications.

\* Troponin I: Troponin T ratio

**Table 3.** Association of troponin I and troponin T (per 1SD increase on the log scale) with risk of different events, adjusted, with both troponins in the same model

	Troponin I Hazard ratio (95%CI)	Troponin T Hazard ratio (95%CI)
CVD (n=1177)	1.23 (1.15 - 1.32)	1.02 (0.94 - 1.09)
CVD death (n=266)	1.42 (1.24 - 1.63)	1.27 (1.07 - 1.50)
Non CVD death (n=374)	0.92 (0.81 - 1.05)	1.39 (1.22 - 1.57)
All cause death (n=640)	1.12 (1.02-1.23)	1.35 (1.22-1.49)
MI (n=259)	1.26 (1.09 - 1.45)	0.85 (0.73 - 0.99)
CHD (n=812)	1.21 (1.12 - 1.31)	0.96 (0.88 - 1.05)
Ischaemic stroke (n=205)	1.36 (1.17 - 1.59)	1.07 (0.90 - 1.27)
Heart failure (n=216)	1.72 (1.51 - 1.95)	1.25 (1.04 - 1.49)
Cancer (n=1078)	0.96 (0.89 - 1.04)	1.01 (0.94 - 1.09)

Model adjusted for age, sex, total cholesterol, HDL-cholesterol, systolic blood pressure, cigarettes smoked per day, rheumatoid arthritis, diabetes, SIMD score, family history of CVD, use of blood pressure medications, use of cholesterol lowering medications, and each troponin adjusted for the other.



**Table 4.** Lead SNPs, and other SNPs in the same loci, with GWAS significant associations with either troponin (at  $p < 5 \times 10^{-8}$ )

Lead SNP	Chromosome	Position	Non-effect allele	Effect allele	Minor allele frequency	P-value	Beta	Other SNPs	Nearest gene
<b>Cardiac troponin I (n=19130)</b>									
rs4253248	4	187155488	G	A	0.4871	$1.25 \times 10^{-08}$	0.050	rs12331618; rs11132382; rs4862669; rs2048; rs4253238; rs1912826; rs3775298; rs1511801; rs4241815; rs4241816; rs4241817; rs4241818; rs4253252; rs3733402; rs4253254; rs4253255; rs66530140; rs35984397; rs4253281; rs4253282; rs1973612; rs4253311	<i>KLKB1, CYP4V2, F11</i>
rs71483973	10	75900464	A	G	0.1679	$2.80 \times 10^{-09}$	0.072	rs11817132	<i>VCL, AP3M1, ADK</i>
rs7481951	11	22271870	A	T	0.4107	$5.77 \times 10^{-10}$	0.055	rs12790951; rs4635079; rs4244488; rs4244490; rs12807778; rs12290197; rs4275631; rs4478991; rs10833711; rs10833712; rs4408310; rs10741930; rs10833719	<i>ANO5</i>
rs148050755	17	62516959	A	C	0.0026	$3.28 \times 10^{-11}$	-0.774	rs187364357; rs138838734	<i>CEP95, SMURF2</i>
rs2298711	18	57000469	T	A	0.1512	$9.80 \times 10^{-12}$	0.083	rs117153087; rs12604758; rs41468947; rs17696641; rs12604424; rs12608430; rs149168942; rs77905572; rs4940867; rs78723480	<i>CPLX4, LMAN1</i>
<b>Cardiac Troponin T (n=19127)</b>									
rs16862512	1	169649691	T	C	0.0050	$3.34 \times 10^{-08}$	0.349		<i>C1orf112</i>
rs548487604	2	85111553	G	C	0.0014	$9.29 \times 10^{-09}$	0.749		<i>TRABD2A</i>
rs75898208	4	186911043	G	A	0.0017	$1.69 \times 10^{-09}$	0.735		<i>SORBS2</i>
rs184140292	9	8457116	T	C	0.0017	$9.84 \times 10^{-09}$	0.706		<i>PTPRD</i>





## Figure Legends

**Figure 1.** Association of hsTnI and hsTnT unadjusted and adjusted (as per table 2) with the composite CVD event. The referent (HR=1) is undetectable levels of hsTnI and hsTnT respectively. Both splines on log scale.

**Figure 2.** Rates of CVD per 1000 person years (n=1,177 events) by low/intermediate/high groupings of both cTnI and cTnT. For cTnI: low  $\leq 1.8$  ng/L (n=9426), intermediate 1.9-3.0 ng/L (n=5052), high  $\geq 3.1$  ng/L (n=5023). For cTnT: low  $\leq 3.0$  ng/L (n=9106), intermediate 3.0-5.7 ng/L (n=5200), high  $\geq 5.8$  ng/L (n=5195).



**Figure 3.** Manhattan plots for SNPs associated with hsTnI (a) and hsTnT (b) after adjustment for age and sex (n=19,130). The horizontal black dotted line indicates genome-wide significance at  $p < 5 \times 10^{-8}$ , and the horizontal grey dotted line suggestive significance at  $p < 1 \times 10^{-5}$ .



Circulation

